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Abstract: Aims: Determining the origin of metastases is an important task of pathologists to allow for
the initiation of a tumor-specific therapy. Recently, homeobox protein Hox-B13 (HOXB13) has been
suggested as a new marker for the detection of prostatic origin. The aim of this study was to evaluate
the diagnostic sensitivity of HOXB13 in comparison to commonly used immunohistochemical
markers for prostate cancer. Materials and methods: Histologically confirmed prostate cancer lymph
node metastases from 64 cases were used to test the diagnostic value of immunohistochemical
markers: prostate specific antigen (PSA), Prostatic acid phosphatase (PSAP), prostate specific
membrane antigen (PSMA), homeobox gene NKX3.1, prostein, androgen receptor (AR), HOXB13,
and ETS-related gene (ERG). All markers were evaluated semi-quantitatively using Remmele’s
immune reactive score. Results: The detection rate of prostate origin of metastasis for single markers
was 100% for NKX3.1, 98.1% for AR, 84.3% for PSMA, 80.8% for PSA, 66% for PSAP, 60.4% for
HOXB13, 59.6% for prostein, and 50.0% for ERG. Conclusions: Our data suggest that HOXB13 on its
own lacks sensitivity for the detection of prostatic origin. Therefore, this marker should be only used
in conjunction with other markers, preferably the highly specific PSA. The combination of PSA with
NKX3.1 shows a higher sensitivity and thus appears preferable in this setting.
Keywords: prostate cancer; metastasis; immunohistochemistry; detection; PSA; PSAP; PSMA;
NKX3.1; prostein; HOXB13; ERG; AR
1. Introduction
Determining the origin of the primary tumor in metastases is an important task of pathologists to
allow for the initiation of a tumor-specific therapy. Since its description in the 1970s, prostate specific
antigen (PSA) has in due course become the dominant prostate marker in serum [1,2]. PSA could be
detected by immunohistochemistry in tissue and was quickly adopted by pathologists as a diagnostic
marker [3,4]. PSA is still regarded as a highly specific marker of prostatic origin, but due to its
decreased or even lost expression in higher grade or metastatic tumors, which was already noted in
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initial studies, its sensitivity is clearly limited, which necessitates the use of additional markers in PSA
negative cases [5]. Prostein, coded by the SLC45A3 gene and identified by transcript profiling studies
of prostate cancer, was found to be highly specific for prostatic origin and displays a characteristic
Golgi-type cytoplasmic staining pattern [6,7]. As seen with PSA, prostein expression also shows a
slightly diminished expression with tumor progression, but in combination with PSA it proved to be
a valuable tool to identify prostatic origin [8,9]. An alternative marker for prostatic origin was the
protein coded by the homeobox gene NKX3.1, which shows nuclear staining on immunohistochemistry
and which was also found to be highly though not exclusively specific for prostate tissues [10,11].
At the 2014 consensus conference of the International Society of Urological Pathology (ISUP), it was
recommended to use immunohistochemistry for PSA, NKX3.1 and prostein to ascertain a prostatic
origin in doubtful cases [5].
Another diagnostic candidate marker that was not considered at that conference was
homeobox protein Hox-B13 (HOXB13), which was characterized as a marker for prostate cancer
by Edwards et al. [12]. HOXB13 also has a nuclear staining pattern and has been recommended by
several studies as a prostate specific marker [13–16]. To date, the diagnostic value and especially the
performance of HOXB13 immunohistochemistry as a marker of prostatic origin in direct comparison
to the commonly used prostate markers (PSA, prostein, ERG, the androgen receptor (AR), NKX3.1,
Prostatic acid phosphatase (PSAP) and prostate specific membrane antigen (PSMA)) in metastases has
not been evaluated, which was therefore the aim of this study.
2. Results
2.1. Immunohistochemical Staining Patterns
All markers showed the expected patterns of immunoreactivity in metastatic prostate cancer.
Prostate specific antigen (PSA) and prostatic phosphatase (PSAP) displayed diffuse cytoplasmic
staining (Figure 1A,C), where prostein showed the characteristic Golgi-type staining (Figure 1B).
Prostate specific membrane antigen (PSMA, Figure 1D) showed a predominantly membranous but
also cytoplasmic immunoreactivity. Nuclear staining was seen for the androgen receptor (AR), ERG,
NKX3.1, and HOXB13 (Figure 1E–H).Int. J. Mol. Sci. 2017, 18, x FOR PEER REVIEW  3 of 9 
 
 
Figure 1. Immunohistochemistry of candidate diagnostic prostate markers. (A) Prostate specific 
antigen (PSA) shows diffuse cytoplasmic staining with a higher degree of heterogeneity in this case. 
(B) Prostein immunoreactivity is restricted to the Golgi apparatus area. (C) Prostate specific alkaline 
phosphatase (PSAP) also displays a diffuse cytoplasmic staining pattern. (D) Prostate specific 
membrane antigen (PSMA) has characteristic cytoplasmic but also membranous staining. (E) 
Androgen receptor shows epithelial nuclear staining. (F) ERG is also located in the nucleus and has a 
higher degree of heterogeneity, as seen here. (G) Homeobox gene NKX3.1 commonly displays strong 
nuclear staining. (H) Homeobox protein HOXB3 is also seen in nuclei, however, the staining intensity 
is weaker. All images are taken in 400×. 
2.2. Statistical Evaluation of Prostate Markers 
The highest detection rate was seen with NKX3.1 followed by the androgen receptor and PSMA. 
PSA, as the most commonly used antibody to specifically recognize prostate cancer, correctly 
detected nearly 81% of cases. ERG labeled, as expected, only 50% of prostate cancer metastases. 
Figure 1. Cont.
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Figure 1. Immunohistochemistry of candidate diagnostic prostate markers. (A) Prostate specific
antigen (PSA) shows diffuse cytoplasmic staining with a higher degree of heterogeneity in this
case. (B) Prostein immunoreactivity is restricted to the Golgi apparatus area. (C) Prostate specific
alkaline phosphatase (PSAP) also displays a diffuse cytoplasmic staining pattern. (D) Prostate specific
membrane antigen (PSMA) has characteristic cytoplasmic but also membranous staining. (E) Androgen
receptor shows epithelial nuclear staining. (F) ERG is also loc ted in the nucl us and has a higher
degree of heterogen ity, as s en here. (G) Homeobox gene NKX3.1 commonly displays strong nuclear
staining. (H) Homeobox protein HOXB3 is also seen in nuclei, however, the staining intensity is weaker.
All images are taken in 400×.
2.2. Statistical Evaluation of Prostate Markers
The highest detection rate was seen with NKX3.1 followed by the androgen receptor and PSMA.
PSA, as the most commonly used antibody to specifically recognize prostate cancer, correctly detected
nearly 81% of cases. ERG labeled, as expected, only 50% of prostate cancer metastases. Prostein, PSAP,
and HOXB13 were only slightly superior, detecting approximately two thirds of cases (Table 1).
Table 1. Detection rates of prostate markers in prostate cancer metastases.
Marker Detection Rate (%) Mean IRS Number of Cases
PSA 80.8 6.3 52
PSAP 66.0 3.5 53
PSMA 84.3 6.0 51
Prostein 59.6 4.2 52
Androgen receptor (AR) 98.1 6.7 53
ERG 50.0 2.6 52
NKX3.1 100.0 8.0 50
HOXB13 60.4 4.7 53
Abbreviations: IRS = immunoreactive Score according to Remmele.
A Spearman rank correlation analysis of IRS values of these markers revealed the following
significant associations: AR and HOXB13 (correlation coefficient (CC) = 0.358, p = 0.009), AR and
NKX3.1 (CC = 0.505, p = 0.001), AR and PSAP (CC = −0.277, p = 0.047), ERG and HOXB13 (CC = 0.283,
p = 0.044), PSA and Prostein (CC = 0.367, p = 0.008), PSA and PSAP (CC = 0.623, p = 0.001), PSA and
PSMA (CC = 0.350, p = 0.012), prostein and PSAP (CC = 0.277, p = 0.049), and prostein and HOXB13
(CC = −0.296, p = 0.035).
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We then investigated which combination of prostate markers would achieve the highest
detection rate by combining the most commonly used marker PSA with the other markers in cross
tables. PSAP recognized 10% of PSA negative cases, which did not add significant information.
PSMA performed slightly better, labelling 50% of PSA negative cases. HOXB13 correctly recognized
70%, and finally NKX3.1 correctly detected all PSA negative cases, leading to a detection rate (of the
combination of PSA and NKX3.1) of 100% in this dataset. Prostein and PSA correctly detected 82% of
cases, HOXB13 and PSA labeled 94.2% of cases correctly, AR and PSA detected 100% of cases, and ERG
and PSA recognized 88% of prostate cancer metastases.
In a direct analysis of HOXB13 and NKX3.1 expression, both markers together recognized 100%,
as NKX3.1 labeled 100% of HOXB13 negative cases. NKX3.1 combined with AR also achieved a
detection rate of 100%.
3. Material and Methods
3.1. Case Selection and Construction of Tissue Microarray
First, prostate cancer patients who underwent radical prostatectomy (RP) and lymphadenectomy
and who were diagnosed at the Institute of Pathology, Charité–Universitätsmedizin Berlin between
1998 and 2005 were identified. Histologically confirmed metastases from 64 cases were used for tissue
microarray construction with one spot per case and a punch size of 1 mm. The tissue microarray
comprised of two blocks. The metastases consisted of 57 local lymph node metastases and seven
systemic metastases (4× bone, 1× penis, 1× oral mucosa, 1× cervical lymph node). Lymph nodes
were submitted to frozen section analysis prior to RP, which was usually not performed in case of a
positive node. Only 13 RPs were performed. Therefore, histopathological RP data on the primary
tumor was not available for the majority of cases. For the thirteen RP cases that were completed,
the Gleason scores (GS) were: GS7-2, GS8-4, GS9-4, GS10-3. The pT categories (according to Union for
International Cancer Control (UICC) TNM classification of malignant tumors, 8th edition) were: pT2-2,
pT3a-1, pT3b-10. Positive margins were seen in 11 cases. The bilateral lymphonodectomy specimens
(n = 57) contained a median of 12 lymph nodes (range 1 to 23). Twenty-nine cases had a single positive
lymph node, 15 cases had two metastases, seven cases had three metastases and six cases had four or
more positive nodes (maximum 11). The use of this tissue was approved by the Charité University
Ethics Committee (EA1/06/2004). No animals were involved in this study.
3.2. Immunohistochemistry
Immunohistochemistry was conducted using semi-automated platforms (Benchmark Ultra,
Roche, and Autostainer, Medac) with protocols that are in routine use at the Institute of Pathology,
University of Bonn (Table 2).
Table 2. Antibodies used for immunohistochemistry in this study.
Antigen Clone Provider Dilution Platform Protocol
PSA Polyclonal, rabbit DAKO 1:20,000 Autostainer No pretreatment
PSAP PASE/4LJ Cell Marque 1:6000 Autostainer HIER (pH 6, 20 s 98 °C)
PSMA 3E6 DAKO 1:500 Benchmark CC1 (pH 8), ultraview
Prostein 10E3 DAKO 1:100 Benchmark CC1 (pH 8), ultraview
Androgen
Receptor (AR) AR441 DAKO 1:400 Autostainer HIER (pH 6, 20 s 98 °C)
ERG EPR3864 Biologo 1:100 Autostainer HIER (pH 6, 20 s 98 °C)
NKX3.1 EP356 Cell Marque 1:200 Benchmark CC1 (pH 8), ultraview
HOXB13 F-9 Santa Cruz 1:50 Benchmark CC1 (pH 8), optiview
Abbreviations: HIER-Heat Induced Epitope Retrieval.
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3.3. Evaluation of Immunohistochemistry
All markers were evaluated semi-quantitatively using the immune reactive score (IRS), which
gives the product of categorized percentage of stained cells (0: negative, 1: 1–10%, 2: 11–50%, 3:
51–80%, and 4: >80%) and staining intensity (ranging from negative (0) to strong (3)), and hence has a
range from 0 to 12. For statistical evaluation, an IRS below 3 was considered a negative test and higher
values were considered as positive, as suggested by Remmele and Stegner in their original proposal
of the IRS scoring system [17]. The evaluation was carried out under the immediate supervision of a
Genito–Urinary pathologist with broad expertise in immunohistochemistry (Glen Kristiansen).
3.4. Statistics
All data were processed using SPSS (IBM SPSS Statistics for Macintosh, Version 22.0, IBM Corp.,
Armonk, NY, USA). Spearman Rank correlations were used to analyze the associations among markers.
4. Discussion
This study evaluates the sensitivity of prostate markers to detect lymph node and distant
metastases of prostate cancer. It confirms that PSA, as the most commonly used antibody for routine
purposes, has a relatively high detection rate of nearly 81%. The value of PSA is its high specificity,
as apart from prostate cancer only breast cancer may be PSA positive, but this is usually not in the closer
differential diagnosis [18]. The loss of PSA expression with tumor dedifferentiation and progression is
long known and constitutes the necessity to use other markers in a combination.
As prostate cancer is an androgen-driven disease, the high rates of androgen receptor expression
found in primary and metastatic prostate tumors are not surprising, and again this study confirms
that metastases retain their AR expression well. The disadvantage of AR is the relative lack of
specificity, as other neoplasms including urothelial carcinoma or salivary gland tumors may also be
AR positive [19,20].
The overexpression of ERG, often resulting from the Transmembrane protease, serine
2-erythroblast transformation-specific-related gene TMPRSS2-ERG translocation which is found in
nearly half of primary prostate cancer cases, is therefore typical of prostate cancer, but with a detection
rate of 50% it clearly lacks sensitivity [21]. It is less well known that even though the genomic
translocation is highly specific for prostate cancer, ERG protein expression is seen in a variety of other
tumors, too. This includes, apart from vascular tumors, round cell sarcomas and leukemias, the more
common differential diagnosis of urothelial carcinoma and, according to the human protein atlas
(hppt://www.proteinatlas.org), also melanoma, testicular, and gastrointestinal tumors [22–24].
Prostein was described and characterized by Xu et al. as a prostate specific protein, which was
quickly used by surgical pathologists for the differential diagnosis of prostate cancer, especially to rule
out urothelial carcinoma, which is almost consistently prostein-negative [6,7,9,25,26]. Prostein also has
the advantage of a distinctive Golgi-type staining pattern, which can be reassuring in cases with only
weak positivity. In primary prostate cancer, prostein expression is inversely correlated with Gleason
scores and is a prognostic marker of disease progression [27]. As our study confirms, the sensitivity of
prostein in metastases is fairly limited with a detection rate of 59%, and even in conjunction with PSA
only 82% of cases can be confirmed as prostatic in origin, which equals the detection rate of PSA alone
in our cohort. As we found that both markers correlated, this redundancy of diagnostic information
is not surprising. The same holds true for PSAP, which we found strongly and highly positively
correlated to PSA, and this did not add significant information as only 10% of PSA negative cases were
picked up by PSAP. A larger cohort may be necessary to demonstrate the additional diagnostic value
of prostein or PSAP to PSA.
Prostate specific membrane antigen (PSMA) is overexpressed during tumor progression,
and Bostwick et al. found 82% positivity rates in primary prostate cancer [28]. However, despite its
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name it is not prostate specific at all, but is also seen in a wide variety of tumors including colon,
bladder, and renal cancer, so its use as a marker for prostatic differentiation is now discouraged [29].
NKX3.1 is a homeobox gene that shows a prostate and testis specific expression pattern, but may
also be found in breast cancer. Its crisp nuclear staining pattern and its high rate of positivity in
metastases (98.6%, Gurel et al. [30]), which this study confirms, have made it a popular diagnostic
marker that is already endorsed by ISUP in their recommendations on diagnostic markers for
genito–urinary pathology [11,30–33]. In particular, its combination with PSA is promising, as the high
detection rate of 100% found in this study witnesses.
HOXB13 is another, so far less acknowledged diagnostic marker candidate, which has been
recommended lately as a prostate specific marker [12,13,15,16]. Barresi et al. analyzed 15 prostate
cancer metastases and found all of them strongly positive (in >75% of tumor cells) which equates a
sensitivity of 100% [15]. Minimally lower rates were reported by Varinot et al., who analyzed 74 cases
of lymph node metastases and 15 additional bone metastases. They found HOXB13 positivity in 33%
of bone metastases and 93% of lymph node metastases. Interestingly, the expression of HOXB13 was
also found as an independent prognostic marker in primary prostate cancer and to correlate with AR
expression [14]. While our study confirms the significant association with AR, the diagnostic value of
HOBX13 appears less convincing, as only 60.4% of prostate cancer metastases were positively stained.
Of course, besides aspects of cohort composition that may influence the tumor biology, technical
issues of the immunohistochemistry protocol or the tissue micro array construction may also explain
this rather significant discrepancy. This detection rate increased markedly to 94.2% if combined with
PSA, but it remains inferior to the combination of PSA with NKX3.1. HOXB13 is also expressed in
other carcinomas including endometrial cancer, which in itself does not limit its diagnostic value,
but also in pancreatic cancer and hepatocellular carcinoma [34–36]. In light of these data, we do not
recommend HOXB13 as a sole marker to detect a prostatic origin in a metastasis, but rather prefer
PSA in conjunction with NKX3.1. However, prostein or HOXB13 may well be considered as third line
markers in doubtful cases, and here combinations are advisable and often necessary [5,37].
This study has several weaknesses. The number of cases is relatively small, which precludes a
more detailed analysis of combinational subgroups. Still, the cohort size is large enough to confirm
the known expression rates of the markers under question and it is the first study to critically analyze
HOXB13 in direct comparison to these other markers in prostate cancer metastases. This study is
restricted to the correct detection of prostate markers in known prostate metastases and hence only
evaluates the sensitivity of these markers. Also, this study lacks data on the Gleason scores of biopsies
of primary tumors, which precludes further correlation analyses of biomarker expression. Finally,
we did not aim to verify the specificity of our candidate biomarkers, which would have necessitated
an additional large analysis of non-prostatic neoplasms [38].
In summary, our data suggest that the novel marker candidate HOXB13 alone is not a good
diagnostic marker for the detection of prostatic origin. Only in combination with PSA does it achieve
satisfactory detection rates. Alternatively, the combination of PSA with the already well-established
marker NKX3.1 shows an even higher sensitivity and is therefore recommended in this setting.
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